Pharmacology: Pharmacokinetics — Clinical Reference Document

Pharmacology · Clinical Bases

How it begins

Análisis exhaustivo y clínicamente orientado de los procesos LADME, los parámetros farmacocinéticos fundamentales, los modelos matemáticos de descripción, las poblaciones especiales y las aplicaciones terapéuticas de la monitorización de fármacos.

What it covers

1. Fundamentals of Pharmacokinetics and the LADME Scheme
2. · 1.1 The LADME Scheme: Integrative Conceptual Framework
3. · 1.2 Transmembrane Transport Mechanisms
4. Release and Absorption From the Site of Administration to Systemic Circulation
5. · 2.1 Pharmaceutical Forms and Release
6. · 2.2 Gastrointestinal Absorption Mechanisms
7. · 2.3 Routes of Administration: Pharmacokinetic Characterization
8. · 2.4 Bioavailability (F): Concept, Types and Determinants
9. · 2.5 The First Pass Effect: Hepatic and Intestinal
10. Distribution Volume of Distribution, Protein Binding and Physiological Barriers
11. · 3.1 Apparent Volume of Distribution (Vd)
12. · 3.2 Binding to Plasma Proteins: Albumin, α1-AGP and Lipoproteins
13. · 3.3 The Blood-Brain Barrier (BBB): Structure and Transport
14. · 3.4 Placental Barrier and Breastfeeding: Pharmacological Considerations
15. Metabolism / Biotransformation CYP450 System, Phases I and II, Pharmacogenomics
16. · 4.1 Phase I and Phase II Reactions
17. · 4.2 The CYP450 System: Isoforms, Substrates, Inducers and Inhibitors
18. · 4.3 Pharmacogenetic Polymorphisms of Metabolism
19. · 4.4 Enzyme Inducers and Inhibitors: Mechanisms and Consequences
20. · 4.5 Prodrugs and Active Metabolites: Therapeutic Relevance
21. Excretion Renal, Biliary Elimination and Total Clearance
22. · 5.1 Renal Elimination: The Predominant Mechanism
23. · 5.2 Biliary Excretion and Enterohepatic Circulation
24. · 5.3 Other Excretion Routes
25. · 5.4 Clarification (Cl): Integrative Concept
26. Pharmacokinetic Parameters AUC, Cmax, Tmax, t½, Steady State and Models
27. · 6.1 The Fundamental Parameters of the C-t Curve
28. · 6.2 Steady State (Steady State, Css)
29. · 6.3 Loading Dose and Maintenance Dose
30. · 6.4 Pharmacokinetic Models: Compartments
31. Order 1, Order 0 and Michaelis-Menten Elimination Kinetics: Phenytoin and Ethanol
32. · 7.1 First Order Kinetics (Linear)
33. · 7.2 Zero Order Kinetics (Non-Linear by Saturation)
34. · 7.3 Michaelis-Menten Kinetics: Phenytoin, Ethanol and Non-Linearity
35. Special Populations IR, IH, Pediatrics, Geriatrics, Pregnancy and Obesity
36. · 8.1 Renal Failure (IR): Dose Adjustment
37. · 8.2 Liver Failure (LI): Child-Pugh and MELD
38. · 8.3 Pediatric Pharmacokinetics: From Neonate to Adolescent
39. · 8.4 Geriatrics: The Multiple Pharmacokinetic Changes of Aging
40. · 8.5 Pregnancy and Obesity
41. Comprehensive Clinical Applications TDM, Interactions, Pharmacogenomics and PK/PD
42. · 9.1 Therapeutic Drug Monitoring (TDM)
43. · 9.2 Pharmacokinetic Interactions: Mechanisms and Risk Classification
44. · 9.3 Pharmacogenomics in Clinical Practice: Current Implementation
45. · 9.4 Pharmacokinetics / Pharmacodynamics Integration (PK/PD)